Floatz logo

Ferriprox

Iron Hemosiderosis

Ain Shams UniversityPhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Iron Hemosiderosis cohort.

Asset / SponsorPhaseRating
Deferasirox
Shire
Phase 4A
DESFERRIOXAMINE B
Ain Shams University
Phase 4BBB
Deferiprone
Ain Shams University
Phase 4BB
DESFERRIOXAMINE B
Ain Shams University
Phase 2/3BB
Deferasirox
Novartis Pharmaceuticals
Phase 2B
DESFERRIOXAMINE B
Novartis Pharmaceuticals
Phase 2B
Deferitazole
Shire
Phase 2CCC

Same molecule, other indications

Ferriprox is also rated in:

beta-thalassemia majorDormant
B
Indicative ·
57 / 100
View asset →
sickle cell diseaseDormant
CC
Indicative ·
45 / 100
View asset →
beta thalassemiaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →